RxDoctor Payments Data

Senthil Selvaraj

Internal Medicine · Boston, MANPI 1417395823

Payments from drug & device makers

$105,806in general payments, 2019–2025

Across 22 payments — averaging $4809.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$105K
  • Abbott$254
  • Boston Scientific$165
  • Alnylam Pharmaceuticals Inc.$116
  • Medtronic$87
  • Novartis$74
  • plus $81 from 3 others

What the payments were for

  • Consulting fees$4,4234%
  • Grants$100,00095%
  • Travel & lodging$4270%
  • Food & beverage$9561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,806 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$21,993
Medicare patients
81
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan73$88,468
FarxigaDapagliflozin Propanediol39$36,644
JardianceEmpagliflozin50$35,563
EliquisApixaban24$30,922
Eplerenone15$922
Spironolactone106$706
Rosuvastatin Calcium25$517
Valsartan12$397
Torsemide17$364
Ezetimibe15$314
Midodrine Hcl16$279
Bisoprolol Fumarate13$224
Potassium Chloride15$208
Carvedilol28$193
Metoprolol Succinate26$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$74$88,46873 claims
AstraZenecaFarxiga$105,029$36,64439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →